On 29 May 2026, Suzhou Basecare Medical Corporation Limited (Basecare) announced that China’s National Medical Products Administration (NMPA) has granted a Class III medical device registration certificate (Guo Xie Zhu Jin 20263180183) for the Gems-series Egg Retrieval Solution, a core reagent used in the first stage of in-vitro fertilisation (IVF).

The solution contains gentamicin sulfate to reduce sample contamination and employs a HEPES buffer system to maintain pH stability outside incubators. It offers a shelf life of up to 52 weeks, enhancing clinical convenience for diverse egg-retrieval procedures.

With this approval, all six Gems-series reagents—egg retrieval solution, embryo processing fluid, fertilisation medium, cleavage embryo culture medium, blastocyst culture medium and embryo culture medium—now hold regulatory certification, establishing a complete, closed-loop product line that spans the entire IVF workflow.

The Gems range draws on three decades of IVF reagent development and was led by embryo-culture specialist David Mortimer of Sydney IVF Centre. Backed by 13 years of multi-centre clinical validation, the series also carries CE, US FDA and Australian TGA clearances, underscoring its global regulatory recognition.

Shareholders and potential investors are advised to exercise caution when dealing in Basecare’s shares.